Thrombomodulin (human 498-amino Acid Fragment)

Thrombomodulin (human 498-amino Acid Fragment) Uses, Dosage, Side Effects, Food Interaction and all others data.

Thrombomodulin (human 498-amino Acid Fragment) is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism.

Thrombomodulin (TM) alfa, a recombinant human soluble TM, enhances activation of pro-carboxypeptidase B2 (pro-CPB2) by thrombin. Activated pro-CPB2 (CPB2) exerts anti-inflammatory and anti-fibrinolytic activities.

Table Of contents

• Thrombomodulin (human 498-amino Acid Fragment)
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Thrombomodulin (human 498-amino Acid Fragment)
Generic	Thrombomodulin Alfa
Thrombomodulin Alfa Other Names	Thrombomodulin (human 498-amino acid fragment), Thrombomodulin Alfa
Type
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.

How Thrombomodulin (human 498-amino Acid Fragment) works

Thrombomodulin alfa is a soluble form of recombinant human thrombomodulin comprising all extracellular domains of thrombomodulin. Bound to thrombin, Thrombomodulin alfa inhibits its procoagulant activity and promotes activation of protein C. Thrombomodulin alfa inhibits thrombin generation by the activation of protein C and the subsequent inactivation of factor Va in the presence of protein S. Thrombomodulin alfa attenuates the extension of the clot by inhibiting further thrombin generation on clots, while other anticoagulants inhibit the initiation of clot formation. A higher concentration of Thrombomodulin alfa is needed to affect clotting time and platelet aggregation than thrombin generation.

Half Life

2–3 days after sc injection; 19.82 +/- 2.10 hours after IV injection

Clearance

7-10 days

Elimination Route

rapidly eliminated through liver

Innovators Monograph

You find simplified version here Thrombomodulin (human 498-amino Acid Fragment)